NASDAQ:WHWK Whitehawk Therapeutics Q3 2026 Earnings Results & Report $3.10 -0.12 (-3.79%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Whitehawk Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.23 versus the -$0.24 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeBefore Market Opens Whitehawk Therapeutics EPS ResultsActual EPS-$0.23Consensus EPS -$0.24Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate5 of last 6 quartersWhitehawk Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesSEC FilingEarnings HistoryCompany Profile Whitehawk Therapeutics Q3 2026 Earnings FAQ Did Whitehawk Therapeutics beat earnings estimates for Q3 2026? Whitehawk Therapeutics (NASDAQ:WHWK) reported earnings of -$0.23 per share for Q3 2026, beating the consensus estimate of -$0.24. The report was announced on Monday, November 9, 2026. Whitehawk Therapeutics Earnings HeadlinesWhitehawk Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 202627 minutes ago | marketscreener.comMWhitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsNovember 9 at 8:00 AM | prnewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 10 at 1:00 AM | Weiss Ratings (Ad)Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Average Target Price of $8.33November 2, 2026 | americanbankingnews.comWhitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 As A Durable ADC Target In Ovarian Cancer And Reinforces Scientific Rationale For HWK-016October 3, 2026 | marketscreener.comMWhitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026October 1, 2026 | prnewswire.comSee More Whitehawk Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Whitehawk Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Whitehawk Therapeutics and other key companies, straight to your email. Email Address About Whitehawk TherapeuticsWhitehawk Therapeutics (NASDAQ:WHWK) is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for the treatment of serious diseases. The company’s activities center on advancing an internal pipeline of therapeutic candidates through preclinical research and clinical development. Whitehawk Therapeutics does not appear to have marketed products at this stage. Its work is focused primarily on research and development, including evaluating potential drug candidates for safety, efficacy and suitability for further clinical testing. Publicly available information about the company’s specific pipeline, operating geographies and leadership is limited. Accordingly, a more detailed description of its products, partnerships or management team cannot be provided without risking the inclusion of unverified information.View Whitehawk Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
